Aug 2026· Oral Oncology· Vol 181, pp.
108110
· 0 citations· 37 references
Medicine
TL;DR
A 3-gene mutational panel as risk stratification model could effectively predict OLK malignant transformation, outperforming pathological grading-based assessment and may provide a foundation for developing personalized management strategies.
Abstract
Objective
To investigate somatic mutations in the whole genes of tissue samples from patients with oral leukoplakia (OLK), as the most typical precursor of oral cancer; and identify the specific genes as a mutational panel for predicting OLK malignant transformation.
Methods
A total of 123 consecutive OLK patients with long-term follow-up (median, 73 months) were prospectively enrolled, and divided into training set (n = 92) and independent test set (n = 31) based on chronological order of enrollment. Genomic DNA was isolated from the fresh-frozen biopsy tissues and somatic mutations in all genes were measured by whole-exome sequencing.
Results
We constructed a 3-gene (TP53, CASP8, and CYP2B6) mutational panel for risk stratification (any mutation vs. no mutation) of OLK malignant transformation. Kaplan-Meier analysis showed that the prognostic power of the 3-gene panel (log-rank P < 0.0001) for risk stratification in malignant progression was better than that of pathological grade in the training and test set, respectively. Multivariate Cox regression analysis revealed that this panel was an independent variable significantly associated with progression in the training (hazard ratio [HR] = 8.05; P < 0.001) and test set (HR = 11.26; P = 0.0421), respectively. The area under the curve (AUC) with 95 % confidence interval was 0.770 (0.648-0.892) and 0.877 (0.705-1.000) in the training and test set, respectively, for predicting malignant transformation in OLK patients.
Conclusions
We established a 3-gene (TP53, CASP8, and CYP2B6) mutational panel as risk stratification model could effectively predict OLK malignant transformation, outperforming pathological grading-based assessment. Such genetic markers may provide a foundation for developing personalized management strategies.
OBJECTIVE
This study aimed to evaluate the predictive value of a quantitative index measuring the extent of somatic copy-number alteration (SCNA) for malignant transformation (MT) in oral leukoplakia (OLK).
METHODS
A prospective cohort of 122 patients with OLK was followed for a median of 74 months. Whole-exome seque...
Oral cavity squamous cell carcinoma (OCSCC) is a common epithelial malignancy for which site-specific biomarkers with proven prognostic utility remain limited. In this study, we present one of the largest single-center, site-specific molecular analyses of OCSCC to date. Using two separate versions of multigene next-gen...
M. Afkhami, N. Haghighi, H. Ma et al.· Head and Neck Pathology· 0 citations
Neuroendocrine neoplasms (NENs) are a diverse group of rare cancers with high heritability and limited treatment options for metastatic disease. Genomic testing guidelines for patients with NENs are limited to germline testing in high-risk individuals and tumour mutational burden (TMB) in a subset of patients. Here, we...
Emma Boehm, Aidan J. Flynn, Wing Fai Nip et al.· Endocrine-Related Cancer· 0 citations
Objectives Although several biomarkers have been described for predicting malignant transformation in oral leukoplakias (OLs) and proliferative verrucous leukoplakias (PVLs), no systematic review has comprehensively evaluated tissue-based genomic instability markers. This review aimed to evaluate the evidence for these...
B. Quah, Yang Zhang, R. Nagadia et al.· Frontiers in Oral Health· 0 citations
SMARCA4 alteration class and allelic status define biologically and clinically distinct subsets of tumors and support incorporating allelic status and functional mutation class into patient selection strategies for emerging BRM-targeted therapies.
M. Repetto, M. Gormally, Jason Chang et al.· Clinical Cancer Research· 0 citations
ABSTRACT This study characterized the genomic profile of esophageal squamous cell carcinoma (ESCC) via circulating tumor DNA (ctDNA) to identify predictive biomarkers for efficacy of definitive radiotherapy combined with systemic therapy. In this prospective cohort of 40 ESCC patients, 7 tumor tissues and 71 serial pla...
Shu-Tang Liu, Qi Wang, Chun Han et al.· Cancer Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.